Clare Kahn does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Solid Biosciences Inc., and Stoke Therapeutics, Inc..

2022 was Clare Kahn's most active year for acquiring shares with 3 total transactions. Clare Kahn's most active month to acquire stocks was the month of May. 2025 saw Clare Kahn paying a total of $9,924.40 for 79,360 shares, this is the most they've acquired in one year.